Acotec (先瑞达) Pre-IPO: Early Mover Advantage in Peripheral DCB
Acotec is early in the peripheral artery drug coated balloon device market with a dominant market share for above-the-knee stenosis. Having said...
368 Views
Zylox-Tonbridge IPO: DCF Valuation Offers Decent Upside to the Upper End
Our valuation offers a price per share of HK$46.42 which is 8.7% higher than the Upper end of the company’s indicative IPO price range of HK$39.8...
361 Views
Zylox-Tonbridge IPO: Valuation Insights
Our base-case DCF valuation is HK$48.56 per share, which is an 18% upside to the mid-point of the IPO price range of HK$39.80-42.70 per share....
350 Views
Zylox-Tonbridge IPO: Comprehensive Coverage, Proven Marketing and Core Products Show Good Potential
Zylox's revenues in 2020 includes only 2-3 months of revenues from the two core products, however, the two products together accounted for about...
272 Views
Zylox-Tonbridge IPO: Living On
Zylox-Tonbridge has launched an HKEx IPO to raise net proceeds of $300 million at the mid-point of the IPO price range. Overall, we believe that...
400 Views